Clinical Trials Logo
  1. Home
  2. Metastatic Lung Cancer
  3. NCT04804137

Immune Response Under Immunotherapy in Metastatic NSCLC: Sputum, Blood Samples and Microbioata Study — RICEPS  

Metastatic Lung Cancer Clinical Trial

Official title:
Immune Response Under Immunotherapy in Metastatic Non-Small Cell Lung Cancer: Sputum, Blood Samples and Microbiota Study

Clinical Trial Summary

Prospective pathophysiological exploratory monocentric study, focusing on adult patients with non-small cell lung cancer (NSCLC) : non-squamous type without oncogenic addiction, metastatic, treated with immune checkpoint inhibitors alone or in combination with chemotherapy in front line at the CHRU de Tours, France.

Clinical Trial Description

The percentage of patients benefiting from immunotherapy is quite low and their systemic side effects can sometimes be severe. One of the main difficulties is to identify before treatment patients who will respond to immune checkpoint inhibitors. Currently, the selection is done in a very large majority of cases on the expression of PD-L1 by the tumor. But this biomarker is not sufficient to identify patients responding or not to immune checkpoint inhibitors. In addition, factors extrinsic to the tumor, to its microenvironment and patient immunity may be involved in the response to immunotherapy such as the microbiota. The investigators therefore assume that the immune response in place during immunotherapy treatment differs according to the profile of patient response to immunotherapy. The main objective of this project is to describe local and systemic anti-tumor immune system of patients responders or not to immune checkpoint inhibitors, but also whether the immunological characterization of sputum could be a reflection of the microenvironment tumor. The secondary objective is to study the intestinal microbiota tract of patients receiving immunotherapy, depending on their consumption of antibiotics, and compare it to the pulmonary microbiota. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04804137
Study type Observational
Source University Hospital, Tours
Contact
Status Completed
Phase
Start date May 3, 2021
Completion date July 31, 2023
View Details
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03177291 - Pirfenidone Combined With Standard First-Line Chemotherapy in Advanced-Stage Lung NSCLC Phase 1
Recruiting NCT05846594 - A Study to Evaluate the Impact of Liquid Biopsy in Participants With a Clinical Diagnosis of Advanced Cancer Phase 4
Not yet recruiting NCT03514329 - Vapor Ablation for Localized Cancer Lesions N/A
Recruiting NCT05502913 - Fecal Microbiota Transplantation With Immune Checkpoint Inhibitors in Lung Cancer Phase 2
Recruiting NCT06060613 - Safety and Efficacy of OBX-115 in Advanced Solid Tumors Phase 1/Phase 2
Active, not recruiting NCT00986661 - A Study to Assess PV-10 Chemoablation of Cancer of the Liver Phase 1
Completed NCT01543672 - Irradiation of Large Lung Tumors or Two or More Lung Metastases Simultaneously Phase 1/Phase 2
Completed NCT03198468 - Vapor Ablation for Localized Cancer Lesions of the Lung (VAPORIZE) N/A
Recruiting NCT06180460 - CALM: Managing Distress in Malignant Brain Cancer N/A
Recruiting NCT06343402 - Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer Phase 1
Recruiting NCT04940325 - Datopotamab (DS-1062a) in Advanced and/or Unresectable Non-Small Cell Lung Cancer Phase 2
Active, not recruiting NCT05241873 - (Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations Phase 1/Phase 2
Recruiting NCT05256290 - Phase 1/2 Study of BDTX-1535 in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR Mutations Phase 1/Phase 2
Completed NCT05908799 - Emulation of the KEYNOTE-189 Trial Using Electronic Health Records
Active, not recruiting NCT03867175 - Immunotherapy With or Without SBRT in Patients With Stage IV Non-small Cell Lung Cancer Phase 3
Recruiting NCT05609578 - Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation Phase 2
Recruiting NCT04708483 - DCE-CT of Thoracic Tumors as an Early Biomarker for Treatment Monitoring in Comparison With Morphologic Criteria N/A
Completed NCT01307501 - Safety and Efficacy of Cryoablation for Metastatic Lung Tumors N/A
Recruiting NCT03143322 - Standard Treatment +/- SBRT in Solid Tumors Patients With Between 1 and 5 Bone-only Metastases N/A
Recruiting NCT05143970 - A Phase 1 First-In-Human Study of the Anti-CD73 IPH5301 Alone or in Combination With Chemotherapy and Trastuzumab in Patients With Advanced Solid Tumors Phase 1